Clinical characteristics and medication patterns in patients with COPD prior to initiation of triple therapy with ICS/LAMA/LABA: A retrospective study - 31/08/18
, Richard H. Stanford a , Tyler Reinsch a, b , Michael Hull c , Ami Buikema c , Erin Hulbert c Abstract |
Background |
This study assessed patient-level characteristics and patterns of medication use in patients with chronic obstructive pulmonary disease (COPD) before initiation of multiple inhaler triple therapy (MITT; long-acting muscarinic antagonist/long-acting β2-agonist/inhaled corticosteroid [ICS/LAMA/LABA] combination).
Methods |
This retrospective study was conducted using the Optum Research Database. Patients enrolled in commercial or Medicare Advantage Prescription Drug plans, with a COPD diagnosis and >1 prescription for a COPD medication between January 2014 and March 2016 were included. The dispensing date for the first pharmacy prescription completing MITT with at least 1 day of overlap was the patient's index date. The 12 months prior to this date were used to assess patient characteristics, exacerbations, eosinophil counts and changes in medication.
Results |
The study population comprised 13,701 patients. At the index date, most patients were using a LAMA (n = 13,353 [97.5%]) and combination ICS/LABA (n = 13,292 [97.0%]) MITT. Overall, 90.4% of patients used a LABA, LAMA, LAMA/LABA, or ICS/LABA or had a moderate or severe exacerbation at any time during the baseline period, indicating that approximately 10% of patients initiated MITT without prior bronchodilator use or exacerbation history. Over 65% of patients with an eosinophil measurement had a value ≥ 150 cells/μL.
Conclusion |
Overall, it appears that in this patient population, ICS/LAMA/LABA as triple therapy is being initiated after use of a bronchodilator and/or after an exacerbation event, in accordance with accepted treatment recommendations.
Le texte complet de cet article est disponible en PDF.Highlights |
• | 59.8% of patients had a moderate/severe exacerbation prior to initiating MITT. |
• | 90.4% of patients were on COPD medication or had an exacerbation prior to MITT. |
• | 9.6% of patients initiated MITT without prior COPD medication use or exacerbations. |
• | Eosinophil results were available for 3109 patients and 79.5% had normal counts. |
Keywords : 3–6), Chronic obstructive pulmonary disease, Triple therapy, Exacerbation, Inhaled corticosteroid, Long-acting muscarinic antagonist, Long-acting β2-agonist
Abbreviations : COPD, ED, FEV1, GOLD, ICD-9-CM/ICD 10-CM, ICS, LABA, LAMA, MAPD, MITT, OCS, OP, SABA, SD, SITT, US
Plan
Vol 142
P. 73-80 - septembre 2018 Retour au numéro
Article précédent
- Peripheral endothelial function is positively associated with maximal aerobic capacity in patients with chronic obstructive pulmonary disease
- Anouk W. Vaes, Martijn A. Spruit, Jan Theunis, Emiel F.M. Wouters, Patrick De Boever
- Temporal transitions in COPD severity stages within the GOLD 2017 classification system
- Joan B. Soriano, Michael Hahsler, Cecilia Soriano, Cristina Martinez, Juan P. de-Torres, Jose M. Marín, Pilar de Lucas, Borja G. Cosio, Antònia Fuster, Ciro Casanova, the CHAIN investigators
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?